Capecard (capecitabine) 500 mg 120 tab., CIPLA, India

Interchangeable drugs with the same active ingredient:

capecard

Apsibin

capetero

Capecibex 150

Capecibex 500

Capecitabine

Kaponco

Xeloda

Newcapibine

citine

Ental-Health

Indications:

Mammary cancer:

• local advanced or metastatic breast cancer, in combination with docetaxel after ineffective chemotherapy, including anthracycline drugs;
• local advanced or metastatic breast cancer, as monotherapy with the ineffectiveness of chemotherapy, including taxanes and anthracycline drugs, or if there is a contraindication to anthracycline therapy.

Colon cancer, colorectal cancer:

• colon cancer, in adjuvant therapy after surgical treatment of stage III cancer (stage C according to Duke)
• metastatic colorectal cancer.

Stomach cancer:

drug for the first line treatment of advanced gastric cancer, in combination with platinum-based drugs.

Contraindications . Severe, including unexpected reactions to treatment with fluoropyrimidines in history. Hypersensitivity to capecitabine or to any component of the drug, or to fluorouracil. Known deficiency of dihydropyrimidine dehydrogenase. Pregnancy and lactation. Severe leukopenia, neutropenia, thrombocytopenia. Severe liver dysfunction. Severe renal insufficiency (creatinine clearance ) Simultaneous use of sorivudine or its structural analogues such as brivudine. Contraindications to the use of any drug used in combination.

Method of application and dose.

Xeloda ® should only be prescribed by a qualified physician experienced in the use of antineoplastic medicinal products. Close monitoring during the first treatment cycle is recommended for all patients.

Treatment should be discontinued if disease progresses or unacceptable toxicity develops.

The drug is taken orally, no later than 30 minutes after a meal, with water.

monotherapy

Colon cancer, colorectal cancer and breast cancer The recommended daily dose of Xeloda ® as adjuvant therapy is 2500 mg/m 2 body surface area and is used in three-week cycles: taken daily for 2 weeks, followed by a week-long break. The total daily dose of Xeloda ® is divided into two doses (1250 mg/m 2 body surface in the morning and evening). The recommended total duration of adjuvant therapy in patients with stage III colon cancer is 6 months.

combination therapy

Breast cancer in combination with docetaxel The recommended dose for the treatment of metastatic breast cancer is 1250 mg / m 2 2 times a day for 2 weeks followed by a break (in combination with docetaxel 75 mg / m 2 1 time in 3 weeks in the form infusion). Premedication with oral corticosteroids such as dexamethasone is given prior to docetaxel administration according to the instructions for docetaxel use in patients receiving the capecitabine plus docetaxel combination.

Colon cancer, colorectal cancer, gastric cancer: in the combined treatment regimen, the initial dose of Xeloda ® should be reduced to 800-1000 mg / m 2 2 times a day for 2 weeks followed by a week break or to 625 mg / m 2 2 times a day days with continuous use. With the combination of irinotecan (200 mg/m 2 on day 1), the recommended dose is 800 mg/m 2 twice a day for 2 weeks followed by a week break. The inclusion of bevacizumab in the combination regimen does not affect the initial dose of Xeloda ® .

Antiemetics and premedication to ensure adequate hydration are given to patients receiving Xeloda in combination with cisplatin or oxaliplatin prior to cisplatin administration, according to the instructions for use of cisplatin and oxaliplatin. The total recommended duration of adjuvant therapy in patients with stage III colon cancer is 6 months.

The dose of Xeloda ® is calculated on the body surface area. Tables 1 and 2 show standard and reduced dose calculations (see "Dose adjustment during treatment") for the initial dose of Xeloda ® 1250 mg/m 2 or 1000 mg/m 2 .